Close Menu

Bio-Rad

An increase in sale growth for its life science segment was offset by a flat quarter year over year for its diagnostics sales.

Roche said at the AMP annual meeting that it plans to commercialize the system in Europe with CE IVD marking for clinical applications and in the US with a 510(k) exemption.

The approach could allow doctors to more accurately and more easily identify which patients are free from cancer after radiation treatment.

The firm aims to launch the new assay in the first quarter of next year and plans to develop other products for single-cell sequencing library prep.

The company is collecting validation evidence it intends to submit to the FDA next year, which will also support launch of  the test as an LDT.

The company said Q2 sales increased 11 percent on a currency-neutral basis, driven by growth in both its Life Science and Clinical Diagnostics segments.

Bio-Rad tallied net sales of $551.5 million compared to $500.1 million in Q1 2017, driven by growth in both its Life Science and Clinical Diagnostics businesses.

The assay could provide detection of HBV infection at early stages, potentially preventing progression to cirrhosis or hepatocellular carcinoma.

As previously disclosed, Bio-Rad's accounting firm needs more time to complete its audit and the company plans to file the form as soon as possible.

Pages

Mainichi reports that 43 percent of Japanese individuals said they did not want to eat agricultural products that had been modified using gene-editing tools.

Two US Department of Agriculture research departments are moving to the Kansas City area, according to the Washington Post.

Slate's Jane Hu compares some at-home genetic tests to astrology.

In PLOS this week: analysis of polygenic risk scores for skin cancer, chronic pain GWAS, and more.